
Is ‘de-extinction' here? How gene editing can help endangered species
Gene editing's real value is not in re-creating copies of long-extinct species like dire wolves, but instead using it to recover ones in trouble now.
Red Wolves are seen at the North Carolina Museum of Life + Science on Thursday, November 8, 2017, in Durham, NC. [Photo: Salwan Georges/The]
BY
Listen to this Article More info
0:00 / 8:48
Have you been hearing about the dire wolf lately? Maybe you saw a massive white wolf on the cover of Time magazine or a photo of Game of Thrones author George R.R. Martin holding a puppy named after a character from his books.
The dire wolf, a large, wolflike species that went extinct about 12,000 years ago, has been in the news after biotech company Colossal claimed to have resurrected it using cloning and gene-editing technologies. Colossal calls itself a ' de-extinction ' company. The very concept of de-extinction is a lightning rod for criticism. There are broad accusations of playing God or messing with nature, as well as more focused objections that contemporary de-extinction tools create poor imitations rather than truly resurrected species.
While the biological and philosophical debates are interesting, the legal ramifications for endangered species conservation are of paramount importance. As a legal scholar with a PhD in wildlife genetics, my work focuses on how we legally define the term 'endangered species.' The use of biotechnology for conservation, whether for de-extinction or genetic augmentation of existing species, promises solutions to otherwise intractable problems. But it needs to work in harmony with both the letter and purpose of the laws governing biodiversity conservation.
Of dire wolves and de-extinction
What did Colossal actually do? Scientists extracted and sequenced DNA from Ice Age-era bones to understand the genetic makeup of the dire wolf. They were able to piece together around 90% of a complete dire wolf genome. While the gray wolf and the dire wolf are separated by a few million years of evolution, they share over 99.5% of their genomes.
Subscribe to the Daily newsletter.Fast Company's trending stories delivered to you every day
SIGN UP
The scientists scanned the recovered dire wolf sequences for specific genes that they believed were responsible for the physical and ecological differences between dire wolves and other species of canids, including genes related to body size and coat color. CRISPR gene-editing technology allows scientists to make specific changes in the DNA of an organism. The Colossal team used CRISPR to make 20 changes in 14 different genes in a modern gray wolf cell before implanting the embryo into a surrogate mother.
While the technology on display is marvelous, what should we call the resulting animals? Some commentators argue that the animals are just modified gray wolves. They point out that it would take far more than 20 edits to bridge the gap left by millions of years of evolution. For instance, that 0.5% of the genome that doesn't match in the two species represents more than 12 million base pair differences.
More philosophically, perhaps, other skeptics argue that a species is more than a collection of genes devoid of environmental, ecological, or evolutionary context.
Colossal, on the other hand, maintains that it is in the 'functional de-extinction' game. The company acknowledges it isn't making a perfect dire wolf copy. Instead it wants to recreate something that looks and acts like the dire wolf of old. It prefers the 'if it looks like a duck, and quacks like a duck, it's a duck' school of speciation.
Disagreements about taxonomy —the science of naming and categorizing living organisms—are as old as the field itself. Biologists are notorious for failing to adopt a single clear definition of 'species,' and there are dozens of competing definitions in the biological literature.
Biologists can afford to be flexible and imprecise when the stakes are merely a conversational misunderstanding. Lawyers and policymakers, on the other hand, do not have that luxury.
Deciding what counts as an endangered 'species'
In the United States, the Endangered Species Act is the main tool for protecting biodiversity.
To be protected by the act, an organism must be a member of an endangered or threatened species. Some of the most contentious ESA issues are definitional, such as whether the listed species is a valid 'species' and whether individual organisms, especially hybrids, are members of the listed species.
Colossal's functional species concept is anathema to the Endangered Species Act. It shrinks the value of a species down to the way it looks or the way it functions. When passing the act, however, Congress made clear that species were to be valued for their 'aesthetic, ecological, educational, historical, recreational, and scientific value to the Nation and its people.' In my view, the myopic focus on function seems to miss the point.
Despite its insistence otherwise, Colossal's definitional sleight of hand has opened the door to arguments that people should reduce conservation funding or protections for currently imperiled species. Why spend the money to protect a critter and its habitat when, according to Interior Secretary Doug Burgum, you can just ' pick your favorite species and call up Colossal '?
Putting biotechnology to work for conservation
Biotechnology can provide real conservation benefits for today's endangered species. I suggest gene editing's real value is not in recreating facsimiles of long-extinct species like dire wolves, but instead using it to recover ones in trouble now.
Projects, by both Colossal and other groups, are underway around the world to help endangered species develop disease resistance or evolve to tolerate a warmer world. Other projects use gene editing to reintroduce genetic variation into populations where genetic diversity has been lost.
For example, Colossal has also announced that it has cloned a red wolf. Unlike the dire wolf, the red wolf is not extinct, though it came extremely close. After decades of conservation efforts, there are about a dozen red wolves in the wild in the reintroduced population in eastern North Carolina, as well as a few hundred red wolves in captivity.
The entire population of red wolves, both wild and captive, descends from merely 14 founders of the captive breeding program. This limited heritage means the species has lost a significant amount of the genetic diversity that would help it continue to evolve and adapt.
In order to reintroduce some of that missing genetic diversity, you'd need to find genetic material from red wolves outside the managed population. Right now that would require stored tissue samples from animals that lived before the captive breeding program was established or rediscovering a 'lost' population in the wild.
Recently, researchers discovered that coyotes along the Texas Gulf Coast possess a sizable percentage of red wolf-derived DNA in their genomes. Hybridization between coyotes and red wolves is both a threat to red wolves and a natural part of their evolutionary history, complicating management. The red wolf genes found within these coyotes do present a possible source of genetic material that biotechnology could harness to help the captive breeding population if the legal hurdles can be managed.
This coyote population was Colossal's source for its cloned 'ghost' red wolf. Even this announcement is marred by definitional confusion. Due to its hybrid nature, the animal Colossal cloned is likely not legally considered a red wolf at all.
Under the Endangered Species Act, hybrid organisms are typically not protected. So by cloning one of these animals, Colossal likely sidestepped the need for ESA permits. It will almost certainly run into resistance if it attempts to breed these 'ghost wolves' into the current red wolf captive breeding program that has spent decades trying to minimize hybridization. How much to value genetic 'purity' versus genetic diversity in managed species still proves an extraordinarily difficult question, even without the legal uncertainty.
Biotechnology could never solve every conservation problem—especially habitat destruction. The ability to make 'functional' copies of a species certainly does not lessen the urgency to respond to biodiversity loss, nor does it reduce human beings' moral culpability. But to adequately respond to the ever-worsening biodiversity crisis, conservationists will need all available tools.
Alex Erwin is an assistant professor of law at Florida International University.
The final deadline for Fast Company's Next Big Things in Tech Awards is Friday, June 20, at 11:59 p.m. PT. Apply today.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CBS News
33 minutes ago
- CBS News
Detecting, monitoring skin cancers made easier with new screening technology
According to the American Cancer Society, more than 100,000 people will be diagnosed with melanoma this year. The good news is now that treatments have advanced, death rates have declined. Diagnostic tools have also vastly improved to detect and monitor skin cancers. Vectra WB180 system takes just seconds to photograph spots Dr. Jonathan Unger, medical director of the Waldman Melanoma and Skin Cancer Center at Mount Sinai, showed CBS News New York the Vectra WB180 system. "Basically, it is a total body photography system," Unger said. "We use 26 cameras to photograph the entire body ... And then the system takes all of these photos, high-resolution photos, and stitches them together into a three-dimensional avatar." The Vectra WB180 system uses 26 cameras to photograph the entire body so doctors can monitor spots on patients' skin. CBS News New York This is relatively new screening technology with about 100 machines across the country. Unger says it takes just a matter of seconds instead of all the time necessary to photograph each individual spot. "Gives us a memory of every spot on the patient's body, right? Once we have a moment in time, we can always look back and say, what did this thing look like? Was it there? Was it not there? Has it been changing?" he said. He adds accessing details of a patient's mole is much quicker, again, taking only seconds. There are additional benefits to this technology, as well. "Decide with greater certainty and more information whether something needs to be checked, tested, biopsied, et cetera," he said. "In our practice, it's really reduced the number of biopsies because a lot of our patients have hundreds, if not more than that, moles, all of which are irregular." He continued, "This allows us to have a higher level of confidence about what we're looking at and making a decision about." "It gives me the ability to take a deep breath and enjoy my life" Patient Jackie Mills has her spots scrutinized with the new machine after a scare several years ago. "In about 2020, I noticed a spot on my face that was new and rapidly changing," she said. But Mills says her dermatologist at that time wasn't that concerned. "I felt like it was getting bigger, changing colors, it was more jagged, and I really had to push and advocate for myself," she said. "Just had a gut feeling that something was wrong, and I was right." Mills was finally diagnosed with melanoma and had Mohs surgery to have the spot removed. "I had to kind of take it in for a minute and be like, I'm going to have a scar on my face for the rest of my life," she said. "It was that or not be here." Now she's checked every six months. "Not only is Dr. Unger looking at my spots, but he's using this machine to mathematically track what's going on from year to year. And I think that's just, it gives me the ability to take a deep breath and enjoy my life and not be constantly worried about melanoma coming back or being an issue," Mills said. The biggest safety tip from doctors is to use sunscreen every day. It can help prevent sunburn, premature aging and skin cancer.
Yahoo
2 hours ago
- Yahoo
Ready-made stem cell therapies for pets could be coming
Earlier this week, San Diego startup Gallant announced $18 million in funding to bring the first FDA-approved ready-to-use stem cell therapy to veterinary medicine. If it passes regulatory muster, it could create a whole new way to treat our fur babies. It's still an experimental field, even though people have been researching stem cells for humans for decades. Seven-year-old Gallant's first target is a painful mouth condition in cats called Feline Chronic Gingivostomatitis (FCGS), which Gallant says could receive FDA approval by early 2026. The field has shown some encouraging early results. Studies on dogs with arthritis showed improvements in pain and mobility, with some benefits lasting up to two years. But when researchers tried similar treatments for kidney disease in cats — that's another condition Gallant wants to tackle — the results were more mixed. What makes Gallant's approach different is convenience. Most stem cell treatments today require harvesting cells from the patient or donors with matching tissue, whereas Gallant's therapy uses ready-to-use cells from donor animals, even if they are a different species. Investors clearly see potential here. The funding round was led by existing backer Digitalis Ventures, with participation from NovaQuest Capital Management, which previously invested in the first FDA-approved human stem cell therapy. The company has an interesting backstory. Gallant's founder, Aaron Hirschhorn, previously sold DogVacay to its biggest rival in the dog-sitting marketplace, Rover. Hirschhorn passed away in 2021; Gallant is now led by Linda Black, who joined as its president and chief scientific officer from nearly the beginning. Gallant has now raised at least $44 million altogether from investors. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
3 hours ago
- Yahoo
Massive Review Finds No 'Safe' Level of Processed Meat Consumption
We know that processed meat isn't particularly good for us, having already been linked to dementia, diabetes, and cancer, but how much of it counts as a 'safe' level of consumption? According to new research, there's no such thing. US researchers reviewed over 70 previous studies (involving several million participants in total), analyzing the relationships between ultra-processed food and three health issues: type 2 diabetes, ischemic heart disease, and colorectal cancer. Associations for processed meat, sugar-sweetened beverages, and trans fatty acids were looked into, and it was the processed meat that came out with the worst results – even if the amount eaten is only small. "The monotonic increases in health risk with increased consumption of processed meat suggest that there is not a 'safe' amount of processed meat consumption with respect to diabetes or colorectal cancer risk," the team from the University of Washington in Seattle writes in their published paper. Related: It's important to put the research into context. The associations found are relatively weak, they don't prove direct cause and effect, and the analyzed studies relied on self-reported dietary habits (which may not be completely accurate). However, the study has several strengths too – it uses a Burden of Proof method, which is more conservative when assessing impacts on health. The results tend to be minimum values, which means they likely underestimate the true health risk. What's particularly notable here is that minimal increases in consumption still raised risk levels. "Habitual consumption of even small amounts of processed meat, sugary drinks, and trans fatty acids is linked to increased risk of developing type 2 diabetes, ischemic heart disease and colorectal cancer," University of Washington nutrition biologist Demewoz Haile told CNN. For example, the equivalent of one hot dog a day was associated with at least an 11 percent greater risk of type 2 diabetes, and at least a 7 percent greater risk of colorectal cancer, compared to eating no processed meat at all. For beverages, an extra can of sugar-sweetened pop a day was linked to a 8 greater risk of type 2 diabetes, and a 2 percent greater risk of ischemic heart disease, compared to not drinking anything sugary. For trans fatty acids, a small daily amount was associated with a 3 percent increase in risk of ischemic heart disease, compared with zero consumption. "This information provides critical data for public health specialists and policymakers responsible for dietary guidelines and potential initiatives that aim to reduce the consumption of these processed foods," write the researchers. While the study has limitations, its scale and conservative methodology make it worth taking note of. This is backed up by a commentary in the same journal, which does note the role of ultra-processed foods in improving food accessibility and shelf life, particularly in areas with limited access to fresh food. The message from the research team is that cutting out ultra-processed foods as much as possible is the best option for our health. The research has been published in Nature Medicine. Ozempic-Like Drugs Could Treat Chronic Migraines, Trial Finds Gut Bacteria Found to Soak Up Toxic Forever Chemicals Gene Therapy Can Restore Hearing in Adults, First-of-Its-Kind Trial Shows